Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been approved for the treatment of patients with metastatic colorectal carcinoma (mCRC) that do not carry KRAS mutations. Therefore, KRAS testing has become mandatory to chose the most appropriate therapy for these patients.In order to guarantee the possibility for mCRC patients to receive an high quality KRAS testing in every Italian region, the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology and Cytopathology -Italian division of the International Academy of Pathology (SIAPEC-IAP) started a program to improve KRAS testing. AIOM and SIAPEC identified a large panel of Italian medical oncologists, pathologists and molec...
International audienceBACKGROUND: The detection of KRAS mutations is mandatory to initiate an anti-e...
Evidence that activating mutations of the KRAS oncogene abolish the response to anti-epidermal growt...
Patients with metastatic colorectal cancer and KRAS mutation are unlikely to benefit from treatment ...
BACKGROUND: Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have ...
Background: Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have ...
In Europe, the use of anti-EGFR monoclonal antibodies is restricted to Kirsten RAS (KRAS) wild-type ...
Novel therapeutic agents targeting the epidermal growth factor receptor (EGFR) have improved outcome...
The use of epidermal growth factor receptor-targeting antibodies in metastatic colorectal cancer has...
Background: In 2014 the European Medicines Agency included exon 2, 3 and 4 KRAS and NRAS testing for...
Metastatic colorectal cancer harboring a mutation in codon 12 or 13 of the KRAS gene does not benef...
Contains fulltext : 69576.pdf (publisher's version ) (Open Access)Novel therapeuti...
KRAS mutation testing is mandatory for patients with metastatic colorectal cancer who are eligible f...
International audiencePURPOSE: Rapid advances in the understanding of cancer biology have transforme...
International audienceBACKGROUND: The detection of KRAS mutations is mandatory to initiate an anti-e...
Evidence that activating mutations of the KRAS oncogene abolish the response to anti-epidermal growt...
Patients with metastatic colorectal cancer and KRAS mutation are unlikely to benefit from treatment ...
BACKGROUND: Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have ...
Background: Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have ...
In Europe, the use of anti-EGFR monoclonal antibodies is restricted to Kirsten RAS (KRAS) wild-type ...
Novel therapeutic agents targeting the epidermal growth factor receptor (EGFR) have improved outcome...
The use of epidermal growth factor receptor-targeting antibodies in metastatic colorectal cancer has...
Background: In 2014 the European Medicines Agency included exon 2, 3 and 4 KRAS and NRAS testing for...
Metastatic colorectal cancer harboring a mutation in codon 12 or 13 of the KRAS gene does not benef...
Contains fulltext : 69576.pdf (publisher's version ) (Open Access)Novel therapeuti...
KRAS mutation testing is mandatory for patients with metastatic colorectal cancer who are eligible f...
International audiencePURPOSE: Rapid advances in the understanding of cancer biology have transforme...
International audienceBACKGROUND: The detection of KRAS mutations is mandatory to initiate an anti-e...
Evidence that activating mutations of the KRAS oncogene abolish the response to anti-epidermal growt...
Patients with metastatic colorectal cancer and KRAS mutation are unlikely to benefit from treatment ...